SLC5A2 and metabolic disease: Hypoglycemic agents, such as metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists, not only have hypoglycemic effects to manage diabetes but additionally have anti-inflammatory properties, which likely contribute to the overall efficacy of these medications in controlling metabolic disease [30].